SAB Biotherapeutics (SABS) EBT Margin (2021 - 2024)
SAB Biotherapeutics' (SABS) quarterly EBT Margin came in at 8347.5% in Q4 2024, down 85375.0% YoY from N/an in Q1 2024, and down 199.44% on a QoQ basis from 2787.69% in Q2 2024.
SAB Biotherapeutics (SABS) EBT Margin (2021 - 2024) Analysis & Trends
SAB Biotherapeutics (SABS) has 4 years of EBT Margin data on file, last reported at 8347.5% in Q4 2024.
- Quarterly EBT Margin fell 85375.0% year-over-year to 8347.5% in Q4 2024, while the trailing twelve-month figure through Dec 2024 was 2441.38% (down 55688.0% YoY) and the FY2024 annual result came in at 3237.31%, down 135281.0% from the prior year.
- EBT Margin slipped to 8347.5% in Q4 2024, from 2787.69% in the prior quarter.
- In the past five years, EBT Margin ranged from a high of 9.13% in Q1 2022 to a low of 8347.5% in Q4 2024.
- A 4-year average of 1976.2% and a median of 363.23% in 2022 frame the typical range for EBT Margin.
- Annual changes were most pronounced in 2023 — EBT Margin sank 796947 bps — and 2024, when it surged 525843 bps.
- Tracing SABS's EBT Margin over 4 years: stood at 104.46% in 2021, then plunged by 248 bps to 363.23% in 2022, then plunged by 1963 bps to 7493.75% in 2023, then retreated by 11 bps to 8347.5% in 2024.
- The last three EBT Margin figures came in at 8347.5% (Q4 2024), 2787.69% (Q2 2024), and 532.06% (Q1 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 41.75% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 35.61% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 34.77% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 18.33% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -94.22% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 12.09% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 13.77% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -2.67% |
| 10 | SAB Biotherapeutics | 308.92 Mn | 308.92 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -8,347.50% |
| Jun 30, 2024 | -2,787.69% |
| Mar 31, 2024 | -532.06% |
| Dec 31, 2023 | -7,493.75% |
| Sep 30, 2023 | -402.59% |
| Jun 30, 2023 | -8,046.13% |
| Mar 31, 2023 | -1,265.50% |
| Dec 31, 2022 | -363.23% |
| Sep 30, 2022 | -197.12% |
| Jun 30, 2022 | -76.66% |
| Mar 31, 2022 | 9.13% |
| Dec 31, 2021 | -104.46% |
| Sep 30, 2021 | -27.66% |
| Jun 30, 2021 | -16.15% |
| Mar 31, 2021 | 8.33% |